title: Modulation of colon tumor oncogene expression by cancer patient-derived lipids.
abstract: In an effort to understand the role of specific fats on carcinogenesis, we have studied the effects of lipids derived from cancer patients on components associated with the regulation of proliferation. The treatment of tumor cells with patient-derived fats produced increased cell proliferation, as indicated by shorter doubling times. The effects of patient-derived lipids on the expression of ras, c-jun, c-erbB-2, and p53 gene products were examined. The cellular expression of the ras proto-oncogene product was increased in both colon tumor cell lines, following lipid treatment. However, c-jun proto-oncogene expression was elevated in HT-29 cells and appeared unchanged in SK-Co-1 cells after lipid treatment. Treatment of HT-29 tumor cells with patient-derived fats produced an enhancement of the p53 gene product, whereas fat treatment reduced p53 expression in SK-Co-1 tumor cells. Further separation of the patient-derived fats indicated that the amplification of p53 gene expression in HT-29 cells could be achieved primarily by addition of the diacylglycerides fraction. Addition of the purified fatty acids, comprising the diglyceride fraction, indicated that the fatty acids, 16:1, 18:0, and 18:1, induced the most significant increases in p53 expression by HT-29 cells. These alterations caused by cancer patient-derived fats are consistent with the loss of normal growth regulation and may explain the epidemiologic association between certain fats and carcinogenesis.
authors.affiliation: Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Kentucky 40202, USA.
authors.forename: D D
authors.initials: DD
authors.lastname: Taylor
authors.forename: C
authors.initials: C
authors.lastname: Gercel-Taylor
authors.forename: J L
authors.initials: JL
authors.lastname: Weese
mesh_terms: D000231:Adenocarcinoma, Papillary / Q000737:chemistry; D001202:Ascitic Fluid / Q000737:chemistry; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D003110:Colonic Neoplasms / Q000235:genetics* / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008055:Lipids / Q000302:isolation & purification / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000737:chemistry; D000090063:Proto-Oncogene Mas; D011519:Proto-Oncogenes / Q000187:drug effects / Q000235:genetics*; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000187:drug effects / Q000235:genetics
chemical_list: D008055:Lipids; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D016159:Tumor Suppressor Protein p53